STAT3 and ovarian carcinoma: The results suggested that administration of NCX-4040, in combination with cisplatin, inhibited tumor growth by inducing apoptosis through downregulation of EGFR and STAT3 signaling in the cisplatin-resistant ovarian cancer xenograft in mice.